Clinical Trial Update: A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy Volunteers [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the effect of solabegron (GW427353) on gastrointestinal transit in healthy volunteers has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome

Drugs mentioned

• Solabegron (solabegron)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Irritable Bowel Syndrome (IBS) | Phase 1 | Status: COMPLETED